<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044214</identifier>
<setSpec>0378-4835</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">New prospectives in non-small cell lung cancer treatment: pharmacogenomics</dc:title>
<dc:description xml:lang="en">The most commonly used chemotherapy strategy in advanced non-small cell lung cancer (NSCLC)today is the combination of two drugs, mainly cisplatin with another drug (gemcitabine, vinorelbine,taxanes, irinotecan). In the last decade attempts have been made to overcome chemotherapy resistancewithout benefit in outcome. There is a &#147;plateau&#148; in the results which seems unable to progress beyondthe frontier of 8-10 months of median survival. At present, research in cancer survival is focused ontranslational pharmacogenomics, with the goal of providing individualized CT based on differentgenetic traits, such a polymorphisms, gen mutation and overexpresion of drug target gene transcripts,and several molecular assays can been used to tailor chemotherapy in the care of lung cancer patients.Accumulated evidence indicates that many genetic markers are related to chemotherapy resistance.One of the most important goals in translational research is to investigate the clinical use of the DNArepair pathways. Several genes such as ERCC1, XPD polymorphisms. RRM1, BCRA1, etc are relatedto cisplatin and other drugs resistance</dc:description>
<dc:creator>Gil Calle,  S</dc:creator>
<dc:creator>Montesa Pino,  A</dc:creator>
<dc:creator>Cobo Dols,  M</dc:creator>
<dc:creator>Alés Díaz,  I</dc:creator>
<dc:creator>Carabante Ocón,  F</dc:creator>
<dc:creator>Benavides Orgaz, M</dc:creator>
<dc:creator>Villar Chamorro,  E</dc:creator>
<dc:creator>Alcaide García, J</dc:creator>
<dc:creator>Gutiérrez Calderón,  V</dc:creator>
<dc:creator>Bretón García, J. J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La estrategia de tratamiento más utilizada en el cáncer de pulmón no microcítico (CPNM) avanzadoes la quimioterapia, concretamente la combinación de dos drogas, principalmente cisplatino con gemcitabina,vinorelbina, taxanos, irinotecan. En el pasado se han hecho intentos en vano de revertir la resistenciaa la quimioterapia. La supervivencia en este estadio no suele superar los 8-10 meses con eltratamiento convencional. En el presente, intentos para superar estos resultados se focalizan en la farmacogenómica,con el objetivo de individualizar la quimioterapia basado en aspectos de biología molecular,como los polimorfismos, mutaciones genéticas, y sobreexpresión de genes que pueden funcionarcomo dianas de los fármacos. La evidencia indica que algunos marcadores genéticos pueden serpredictivos de resistencia a la quimioterapia. Uno de los objetivos en investigación translacional es investigarla aplicación clínica de los sistemas de reparación del DNA. Algunos genes como ERCC1,XPD polymorphisms. RRM1, BCRA1, etc, se relacionan con resistencia a cisplatino y otras drogas</dc:description>
<dc:source>Oncologia;29(2): 55-64, feb. 2006. ilus</dc:source>
<dc:identifier>ibc-044214</dc:identifier>
<dc:title xml:lang="es">Nuevas perspectivas en el tratamiento del cáncer de pulmón no microcítico: farmacogenómica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d32769^s22033</dc:subject>
<dc:subject>^d8352^s22057</dc:subject>
<dc:subject>^d33161</dc:subject>
<dc:subject>^d4328^s22033</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d10788^s22045</dc:subject>
<dc:subject>^d31722^s22057</dc:subject>
<dc:subject>^d8929</dc:subject>
<dc:type>article</dc:type>
<dc:date>200602</dc:date>
</metadata>
</record>
</ibecs-document>
